1. The influence of single-dose intravenous ouabain on haemodynamics, renal function and vasoactive hormones was investigated in healthy subjects. 2. After ouabain injection there was a significant reduction in minimum and average hourly heart rates. Diastolic blood pressure fell immediately after ouabain, without a significant change in systolic blood pressure. 3. There was no change in renal blood flow, glomerular filtration rate, hourly urine volume or sodium and potassium excretion. 4. Ouabain injection was associated with a fall in plasma angiotensin I1 levels and a rise in plasma adrenaline levels, but plasma noradrenaline levels were unchanged. Both plasma atrial and brain natriuretic peptide levels were increased after ouabain administration. 5. The present study demonstrates that ouabain has significant although minor, acute effects on plasma levels of vasoactive hormones. It fails, however, to confirm that ouabain is an acute pressor or natriuretic substance. If it has an important influence on electrolyte and haemodynamic homoeostasis, its actions are likely to be slowly developed.
INTRODUCTION
The existence of an endogenous inhibitor of sodium-potassium ATPase, which may have a causative role in the development of some forms of hypertension, was suggested by Haddy and Overbeck [l] in 1976. Plasma substances have been detected which inhibit sodium-potassium ATPase, but none was fully characterized or shown to be present at relevant plasma concentrations until Ludens et al. [2] isolated an endogenous compound which is identical with plant-derived ouabain on chromatographic separation and mass spectrometry, and in terms of immunoreactivity and binding characteristics. This compound is apparently secreted by the adrenal gland [3] and is present in the plasma of healthy subjects at levels sufficient to exert a physiologically important influence on the sodium pump [4] . Additionally, the substance has been found in increased concentrations in the plasma of both hypertensive patients and volume-loaded subjects [4, 
51.
Existing data on ouabain obtained over almost 100 years refer mainly to its pharmacokinetic profile and its electrophysiological or cardiotonic effects [6-81. There is little detailed information regarding its effects on blood pressure, volume control, or on vasoactive hormones in healthy man. Given the possibility that endogenous ouabain may be an important sodium-potassium ATPase inhibitor, it was our aim to elucidate the short-term effects of ouabain on haemodynamics, renal function and vasoactive hormones, in healthy subjects.
METHODS
The protocol was approved by the Ethics Committee of the Canterbury Area Health Board, and fully informed consent was obtained from all subjects. We studied seven healthy male subjects aged 24-49 (mean 33) years and weighing 62-83 (mean 73)kg, who were on no regular medication. They were studied on two occasions separated by at least 2 weeks, before and after the intravenous injection of ouabain or placebo in a single-blind, placebocontrolled, randomized cross-over fashion. For 3 days before each study, the subjects received a controlled diet, prepared in the metabolic kitchen, of constant sodium (1 50 mmol/day) and potassium (80mmol/day) content. Urine was collected on the day before each study for measurements of sodium and potassium excretion. On each of the 2 study days the subjects were seated from 08.00 to 16.00 hours, standing only to pass urine each hour. On the morning of the studies the subjects received an oral fluid load of 300ml of distilled water at 08.00 hours and subsequently drank 200ml of sterile water every hour. At 10.00 hours they received a single intravenous dose of ouabain (Laboratoire Aguettant, Lyon, France), 0.5mg in lOml of 0.9% NaCl given over 2min, or just lOml of 0.9% NaCl (placebo) given over a similar time interval. Intravenous inulin and p-aminohippurate infusions were given between 08.00 and 16.00 hours for serial measurements of glomerular filtration rate and renal blood flow, respectively. Aliquots were taken from hourly urine samples for measurements of sodium, potassium, creatinine and cyclic GMP. Hourly or half-hourly venous samples were taken between 08.00 and 16.00 hours via an indwelling forearm cannula for measurements of ouabain, plasma renin ativity (PRA), angiotensin 11, aldosterone, cortisol, adrenaline, noradrenaline, atrial and brain natriuretic peptides (ANP and BNP) and plasma cyclic G M P [9, lo] . For each subject hormone measurements on both ouabain and placebo study days were performed in a single assay.
The interassay coefficient of variation was highest for adrenaline (22%) and lowest for noradrenaline For plasma ouabain measurements, 0.5 ml plasma samples were extracted in duplicate through washed, disposable C, cartridges using 25% acetonitrile,' 0.1% trifluoroacetic acid. The eluate was dried down under air (SOOC), reconstituted with 200pl of 5% isopropanol and injected on to a lOcm Brownlee RP18 h.p.1.c. column running a gradient of 4 1 6 % isopropanol over 20 min, followed by 80% isopropanol for 2 min. Fractions (1 ml) were collected for 35min from the column, dried down under air at 50°C and stored at -20°C before assay. Fractions were reconstituted with 400 pI of phosphate buffer before assay. H.p.1.c. fractions were assayed by an indirect e.1.i.s.a. Briefly, ouabainthyroglobulin conjugate was adsorbed to microtitre plates and competed with sample ouabain for a limiting amount of locally raised rabbit antiouabain serum. Unbound ouabain and first antibody were removed and goat-anti-rabbithorseradish-peroxidase-conjugated second antibody was added to each well. After 2h, the plate was washed and horseradish peroxidase substrate was added. Colour development was left to proceed in the dark for 20min, after which the reaction was stopped. Absorbances were read at 492 nm, and ouabain concentrations were determined by interpolating sample absorbances from a ouabain standard curve run on the same plate. Assay sensitivity was less than 0.04mmol/l.
Microhaematocrit levels were checked at 10.00, 11.00, 13.00 and 16.00 hours, and plasma creatinine, sodium and postassium concentrations were determined at the start (08.00 hours) and end (16.00 hours) of each of the 2 study days. Continuous Holter monitor recordings of the electrocardiogram were made between 08.00 and 16.00 hours on both study days. Blood pressure and heart rate measurements were recorded in duplicate every 30 min using a modified Rose box (Electronic Research and Development, Dunedin, New Zealand). For the halfhour period immediately after ouabain or placebo injections, additional recordings were made at 5 min intervals.
Data were analysed by analysis of variance with repeated measures using program P2V of the BMDP package, with treatment (ouabain or placebo) and time as repeated measures factors [ll] . Where appropriate, mean values at specific time points were compared, post hoe, by paired t-test. For variables showing differences at baseline, results were analysed by analysis of co-variance, using the baseline values as co-variates. Results are given as means+SEM. A P value of <0.05 was taken to indicate statistical significance.
RESULTS
Collection of data was complete except for heart rates from Holter recordings, which were lost in two subjects. There were no untoward effects from ouabain or placebo injections. Urine volume (1 879 k 293 and 1600 5 233 ml), urine sodium (149f 12 and 121 k 13 mmol) and urine potassium (66 + 4 and 59 f 2 mmol) were not significantly different over the 24h period before ouabain and placebo injections, respectively. The haematocrit was almost identical just before injection of ouabain and placebo (41 + 1 and 40+ l%, respectively) and was unchanged over the post injection period (41 + 1 and 40+ 1% at 16.00 hours). Baseline plasma ouabain levels were at or below the limits of detection for our assay. Thirty minutes after the intravenous injection of ouabain, plasma ouabain levels were 5.3 & 2.4 nmol/l, and then declined steadily to a nadir of 0.54k0.41 nmol/l 4 h post injection, after which levels remained stable and well above baseline (pre-injection) values (Fig. 1 ).
Haemod ynamics
The heart rate tended to be lower after ouabain injection than after placebo, and this was statistically significant overall for the minimum hourly heart rate (P<O.O2) and over the first hour for the average hourly heart rate ( P =0.001) (Fig. 2) . Sys- tolic blood pressures tended to be higher, and diastolic blood pressures to be lower, after ouabain than after placebo injections, but statistical significance was achieved only for diastolic blood pressures in the 30min after injection (P<O.O3) (Fig. 2) .
Renal/urinary indices
Renal blood flow, calculated from the clearance of p-aminohippurate, was similar in the hour before ouabain and placebo injections and was not different on the 2 experimental days in the first, third and sixth hours after injection (Table 1) . Likewise, glomerular filtration rates, calculated from the clearance of inulin, were similar in the hour before ouabain and placebo injections and again in the first, third and sixth hours after injection ( Table 1) . Time-matched urine volumes and the hourly excretion rates of sodium, potassium and cyclic GMP did not differ between the 2 experimental days ( Table 1) .
Plasma hormones
Plasma adrenaline levels were significantly increased after ouabain injection (P<0.05) (Fig. 3) . Plasma noradrenaline levels, however, did not change (Table 2 ). Both PRA and plasma angiotensin I1 levels tended to be lower after ouabain then placebo injection (Fig. 3) and for angiotensin I1 the difference was statistically significant over the 3 h period after injection ( P < 0.005). Circulating levels of aldosterone rose briefly but not significantly after ouabain injection, whereas plasma levels of cortisol were similar on the 2 study days ( Table 2 ). Statistical analysis revealed that ouabain injection was associated with significantly higher plasma levels of ANP (P<O.Ol) and BNP (P<0.05) than after placebo injection; however, cyclic GMP levels were similar in plasma and urine on both days (Table 2) .
DISCUSSION
Numerous studies point to the existence of endogenous inhibitors of sodium-potassium ATPase [l, 12, 131. Evidence that excessive circulating levels of one or more of these inhibitors contribute to the development of human hypertension has been marshalled [14-171. Indeed, the consequences of raised concentrations of such an inhibitor have been predicted by de Wardener and MacGregor [17] to include not only an elevation of arterial pressure, but also suppression of renin and stimulation of the sympathetic nervous system. These predictions were based on the known effects of ouabain, an inhibitor of sodium-potassium ATPase, under experimental circumstances. In light of these early predictions, it is especially noteworthy that the recent work of Hamlyn and co-workers [2-41 indicates that the circulating digitalis-like factor in man is ouabain and is secreted by the adrenal glands. Circulating immunoreactive ouabain levels are reported to be elevated in patients with hypertension, cardiac failure or hypothyroidism [4] .
If, as is claimed by Gottlieb et al.
[5], ouabain is an endogenous hormone which is involved in the regulation of electrolyte and water balance, control of circulatory dynamics and modulation of vasoactive hormones, it will be important to document its bioactivity in both short-and long-term studies. Early workers directed their attention largely to the effects of ouabain on cardiac electrophysiology or various haemodynamic indices from the perspective that ouabain, a plant-derived drug, had therapeutic potential in patients with tachyarrhythmias or with cardiac failure. In the present study, we measured the short-term consequences of an intravenous injection of ouabain in healthy male subjects insofar as blood pressure, heart rate, vasoactive hormones and renal function are concerned. These indices were measured under standardized conditions of dietary sodium and potassium intake, body posture and time of day, and the results were compared with data collected under identical circumstances after injection of a placebo. The dose of ouabain (0.5mg) was chosen in order to raise plasma levels of the steroid to those reported in certain pathophysiological states. The normal range of endogenous ouabain in plasma has been given as 0.17-0.77 nmol/l [5], with levels in hypertensive patients increased by up to 200% [4] . Such levels were achieved for several hours after ouabain injection in the present study.
Compared with placebo, ouabain reduced the heart rate. The bradycardic effect appeared small, but was consistent from both manual readings and continuous Holter recordings. We presume this results, at least in part, from a stimulation of vagal activity [l8], although our study does not address this issue.
Previous work indicates that digitalis glycosides have a pressor effect in experimental animals and in healthy subjects [7, [18] [19] [20] [21] , although the absence of time-matched control (placebo) data makes interpretation difficult. This pressor effect is believed to result from a direct vasoconstrictor action which is augmented by removal of endothelium [22] , from heightened sympathetic activity through a number of mechanisms including release of catecholamines from sympathetic nerve terminals [23, 241 , and from enhancement of the pressor actions of angiotensin I1 and noradrenaline [25, 261. In the present study, as in that of Yamaji et al. [26] , ouabain had little discernible effect on arterial pressure, systolic pressures tending to rise and diastolic pressures to fall. It is possible that the hormone changes we observed, namely the decline in circulating levels of angiotensin I1 and rise in ANP and BNP, served to counter any pressor action of ouabain. Alternatively, the pressor effect of ouabain might develop slowly, in which case longer-term studies are needed. Certainly in rats given high doses of ouabain by continuous infusion, arterial pressure took approximately 2 weeks to rise [27] . It is noteworthy that, at least in rats, chronic digoxin infusion failed to increase blood pressure [27] ; thus extrapolation of results from studies which have utilized digoxin or other digitalis-like steroids may not necessarily be applicable to ouabain, at least in relation to pressor effects.
Digitalis glycosides, including ouabain, induce a diuresis and natriuresis when injected in large doses directly into the renal arteries in dogs and rats [28- 301 independent of glomerular filtration rate and despite, in some studies, a decline in renal blood flow. This effect is presumed to result, at least in part, from inhibition of tubular reabsorption of sodium [3 13 . In the present study where dietary electrolytes, fluid intake and body posture were carefully controlled, ouabain had no effect on urine volume or urine sodium and potassium excretion when compared with time-matched data after a placebo injection. Likewise, ouabain did not alter renal blood flow or glomerular filtration rate as determined by standard techniques. This is not to say that under different circumstances (in hypertension or heart failure, for example) and particularly with more prolonged administration, ouabain is without discernible effects on renal function.
Digitalis-like glycosides have been shown experimentally to interact with the sympathetic system at multiple sites [18, 21, 23-26, 32, 331 . They appear to have a local vasoconstrictive effect due, in part, to increased neurotransmitter release and reduced uptake. The effect on peripheral levels of catecholamines is less clear. Ribner et al. [32] reported that plasma noradrenaline levels were reduced significantly by digoxin (1 mg intravenously) in patients with heart failure and that these changes correlated with an increase in cardiac output. Plasma adrenaline levels were unchanged. We are not aware of similar information in healthy subjects although Ferguson et al. [21] reported that sympathetic nerve activity to muscle was not altered by the intravenous administration of Cedilanid-D (0.02 mg/kg) despite an increase in arterial pressure. These data were taken to indicate that the glycoside elicited a sympatho-excitatory response, since a fall in sympathetic nerve activity should have been anticipated in response to the rise in arterial pressure [21] . In the pressure study, we observed no change in circulating levels of noradrenaline, but an increase, albeit of minor magnitude, in adrenaline levels. It is possible that ouabain stimulated sympathetic activity in our subjects as manifest by the response in plasma adrenaline, but if so it appears to be a small effect. Clearly, additional information is needed regarding the effects of ouabain on sympathetic activity in normal man.
Although We demonstrated a definite, although small, inhibitory action of ouabain on angiotensin I1 levels and a similar but not statistically significant fall in renin. It is possible that this suppression of the renin-angiotensin system countered any vasoconstrictor/pressor action of ouabain itself. One might question why angiotensin I1 levels were reduced by ouabain, yet aldosterone levels, which are regulated by the octapeptide under many circumstances, were unaltered overall and even tended to rise initially. The answer might lie in the fact that ouabain, at certain concentrations (lo+ mol/l), can increase aldosterone production from rat adrenal glomerulosa cells, and is capable of modifying aldosterone responses to angiotensin I1 and adrenocorticotropic hormone [38] . Again, more information is needed to define the effect of ouabain on aldosterone in healthy man.
Our results indicate a statistically significant stimulatory effect of ouabain on ANP and BNP levels, which is of interest since the glycoside has been demonstrated to stimulate circulating ANP levels in anaesthetized dogs [39] and to increase immunoreactive ANP secretion from, and accumulation of ANP mRNA in, rat cardiocytes in a perfusion system [40] . In addition, it has been shown that ANP regulates the levels of sodium-potassium ATPase inhibitors [41] and that ANP and ouabain have opposite effects on vascular resistance, suggesting the possibility of physiological antagonism [42] .
Although the difference between ouabain and placebo data for ANP and BNP concentrations achieved statistical significance in our study, we doubt its biological significance since mean levels of the two peptides were virtually identical on the two experimental days, and cyclic GMP levels in plasma and urine were unaltered by ouabain. In summary, a single intravenous injection of ouabain in healthy male subjects had little or no discernible short-term effects on arterial pressure, renal function and urinary electrolyte excretion, on plasma noradrenaline, aldosterone and cortisol levels, or on cyclic GMP in plasma or urine. Ouabain did, however, reduce heart rate and suppress circulating levels of angiotensin I1 while stimulating plasma concentrations of adrenaline, ANP and BNP. If endogenous ouabain is involved in electrolyte and haemodynamic homoeostasis, its actions are likely to be slowly developed compared with, for example, the sympathetic system or the renin-angiotensin system.
